MedTrace Logo

Sequential Therapy in Metastatic Renal Cell Carinoma

NCT01731158 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2019-02-06

No results posted yet for this study

Summary

Sequential therapy with BEvacizumab, RAd001 (everolimus) and Tyrosinekinase inhibitors (TKI) in metastatic renal cell carcinoma (mRCC)

Conditions

  • Metastatic Renal Cell Carcinoma

Interventions

DRUG

Avastin in combination with Roferon-A

DRUG

Afinitor

DRUG

TKI: Sutent, Nexavar or Votrient

TKI

Sponsors & Collaborators

  • Central European Society for Anticancer Drug Research

    lead OTHER

Principal Investigators

  • Viktor Grünwald, MD · University Hospital Hannover, Germany

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-10-31
Primary Completion
2016-09-30
Completion
2016-09-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01731158 on ClinicalTrials.gov